Overview
PCRX market data
Price History
PCRX price chart
Valuation & Profitability
- P/E (TTM)
- 62.71 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.16 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.21 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 2.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $18.80 – $27.66 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $918M · P/B 1.61 · P/S 1.23.
Company News
Pacira Biosciences Publishes 2-Yr Phase 1 Results In Annals Of Rheumatic Diseases For PCRX-201 Gene Therapy In Moderate To Severe Knee Osteoarthritis, Showing Tolerability And Improvements In Pain, Stiffness, And FunctionBenzinga · Aug 6, 2026, 12:16 PM
Pacira BioSciences shares are trading lower after the company lowered its FY2026 sales guidance.Benzinga · Aug 5, 2026, 5:40 PM
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $25Benzinga · Aug 5, 2026, 5:00 PM
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33Benzinga · Aug 5, 2026, 11:47 AM
Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M EstBenzinga · Aug 4, 2026, 8:03 PM
Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M EstimateBenzinga · Aug 4, 2026, 8:02 PM
Pacira BioSciences Successfully Transitions PCRX-201 To A Scalable Commercial Manufacturing Process In The U.S.; Topline Data From Part A Of Phase 2 ASCEND Study Remains On Track For End Of 2026Benzinga · Jul 27, 2026, 12:03 PM
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026Globenewswire Inc · Jul 22, 2026, 12:15 PM
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Globenewswire Inc · Jul 8, 2026, 12:15 PM
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price TargetBenzinga · Jul 1, 2026, 12:25 PM